Abstract
Objective:To systematically evaluate the clinical efficacy and safety of Western medicine plus the Qili Qiangxin capsules(芪苈强心胶囊)on heart failure plus atrial fibrillation.Methods:Randomized controlled trial studies met the inclusion criteria were retrieved from CNKI,Wanfang,VIP,China biomedical literature database,PubMed,and Web of Science databases.Two researchers independently conducted literature screening,data extraction,and quality assessment,and the statistical analysis was performed by RevMan 5.4 software.Results:A total of 17 studies involving 1 568 patients were included.The Meta-analysis demonstrated that the Qili Qiangxin capsules as an adjuvant therapy significantly improved the overall clinical efficacy[RR=1.23,95%CI(1.17,1.28),P<0.000 01],ameliorated cardiac function indicators such as left ventricular ejection fraction[MD=5.62,95%CI(4.61,6.62),P<0.000 01],left ventricular end-systolic diameter[MD=-5.52,95%CI(-6.62,-4.42),P<0.000 01],left ventricular end-diastolic diameter[MD=-6.56,95%CI(-8.16,-4.97),P<0.000 01],cardiac index[MD=0.58,95%CI(0.09,1.06),P=0.02],and cardiac output[MD=0.63,95%CI(0.39,0.87),P<0.000 01]),and reduced QT interval dispersion[MD=-6.39,95%CI(-7.02,-5.76),P<0.000 01],serum N-terminal pro-B-rain natriuretic peptide(NT-proBNP)[MD=-407.94,95%CI(-647.82,-168.06),P=0.000 9],matrix metalloproteinase 9(MMP9)[MD=-44.15,95%CI(-83.66,-4.64),P<0.000 01],and tumor necrosis factor-α(TNF-α)[MD=-3.51,95%CI(-5.99,-1.03),P=0.006]levels.No significant increase in the risk of adverse events was observed[MD=0.63,95%CI(0.29,1.39),P=0.260].Conclusion:The Qili Qiangxin capsules as an adjunctive therapy for heart failure plus atrial fibrillation demonstrates significant advantages in improving the overall clinical efficacy,as well as in ameliorating cardiac function,electrophysiological stability,and biomarker levels of patients,with favorable safety.However,more high-quality randomized controlled trials are warranted to further strengthen the evidence.关键词
芪苈强心胶囊/心房颤动/心力衰竭/随机对照试验/Meta分析Key words
The Qili Qiangxin capsules/Atrial fibrillation/Heart failure/Randomized controlled trial/Meta-analysis分类
医药卫生
